Unravel Announces Collaboration with Vanderbilt University Medical Center to Support Upcoming Multicenter U.S. Clinical Study in Rett Syndrome that Includes RVL-001

Posted on by

Multisite trial run by Vanderbilt will evaluate repurposed FDA-approved drugs as treatment options for Rett syndrome patients, including vorinostat (RVL-001) predicted by Unravel’s BioNAV platform. BOSTON, May 14, 2024 /PRNewswire/ — Unravel Biosciences, Inc., (“Unravel”), an AI-enabled…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.